Following a positive Phase II readout, Amplyx plans to take lead candidate fosmanogepix into a Phase III head-to-head trial against echinocandins as first-line treatment for invasive Candida infections. Echinocandins are standard of care in the...

Investors in VarmX’s €32 million ($36.1 million) series B round brought together a deep-pocketed syndicate designed to support the Netherlands-based coagulation play through registrational studies for its lead program. INKEF Capital and Ysios Capital co-led...

Aiming to develop precision cancer therapies that can treat more patients, Kinnate emerged from stealth Thursday with $74.5 million in an untranched series B from new investors OrbiMed Advisors, Nextech Invest and Vida Ventures. Foresite...

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001. On Aug. 2, the biotech raised $67 million...

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain...

Peter Reikes, Vice Chairman, Stifel Nicolaus & Co., Ario Arabi, Associate, Stifel Nicolaus & Co. and Peter Nie, Analyst, Stifel Nicolaus & Co. Among the most popular explanations for the significant equity market moves in...